Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q1 FY27 results · Apr–Jun 2026
Marksans Pharma reported revenue from operations of ₹840.80 crore (up 35.6% from Q1 FY26) and net profit of ₹159.41 crore (up 173.9% from Q1 FY26) for Q1 FY27 (Apr–Jun 2026), on a consolidated basis.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 840.80 | 619.99 | +35.6% | 856.11 | −1.8% |
| Other income | 25.40 | 5.64 | +350.3% | 35.17 | −27.8% |
| Total income | 866.20 | 625.63 | +38.5% | 891.29 | −2.8% |
| Profit before tax | 206.57 | 76.60 | +169.7% | 200.00 | +3.3% |
| Net profit for the period | 159.41 | 58.20 | +173.9% | 149.03 | +7.0% |
| Attributable to shareholders of the company | 157.17 | 58.32 | +169.5% | 148.13 | +6.1% |
| EPS, basic (₹) | 3.47 | 1.29 | +169.0% | 3.27 | +6.1% |
| Net margin (%) | 19.0 | 9.4 | 17.4 |
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 321.19 | 319.73 | +0.5% | 361.57 | −11.2% |
| Other income | 17.47 | 2.01 | +769.2% | 27.48 | −36.4% |
| Total income | 338.66 | 321.74 | +5.3% | 389.05 | −13.0% |
| Profit before tax | 90.46 | 63.57 | +42.3% | 124.36 | −27.3% |
| Net profit for the period | 69.04 | 48.06 | +43.7% | 91.92 | −24.9% |
| EPS, basic (₹) | 1.52 | 1.06 | +43.4% | 2.03 | −25.1% |
| Net margin (%) | 21.5 | 15.0 | 25.4 |
Consolidated
- Filed with BSE
- 12 Aug 2026, 14:45 IST
- Board meeting
- 12 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 Aug 2026, 14:45 IST
- Board meeting
- 12 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE